Medical Services & Publications

SHERIDAN, WYOMING – November 10, 2024 – Shockwave Medical, a Johnson & Johnson MedTech company, has announced encouraging results from its DISRUPT BTK II study, which investigated the use of Intravascular Lithotripsy (IVL) in patients

SHERIDAN, WYOMING – November 09, 2024-Company Maintains Positive Outlook for the Remainder of the Fiscal Year FUJIFILM Holdings Corporation today announced strong financial results for the first half of the fiscal year ending March 31, 2025. The company reported a 9.1% year-over-year increase in revenue, reaching JPY1,514.7 billion. This growth was primar

SHERIDAN, WYOMING – November 9, 2024 – Terumo Corporation (TSE: 4543) today announced a series of strategic leadership appointments to further strengthen its global operations and drive continued innovation in medical technology. The changes, effective October 1, 2024, included key positions within the Cardiac and Vascular Company and Terumo Americas Holding, Inc. New Leadership Appointments Fumihisa Hirose was promoted to Group Managing Executive Officer and President of the Cardiac and Vascular Company. Mr. Hirose previously served as President of the Cardiac and Vascular Company and Division President of the Interventional Systems Division.

SHERIDAN, WYOMING – November 09, 2024– In a move set to transform blood processing in the United States, Terumo Blood and Cell Technologies (Terumo BCT) has launched the Reveos™ Automated Blood Processing System. This innovative technology, already used in over 50 countries for more than a decade, promises to significantly enhance efficiency and address critical platelet shortages. "Reveos is a revolutionary technology that automates whole blood processing. By streamlining the process, it significantly improves efficiency and consistency compared to traditional manual methods used by U.S. blood centers," says Chetan Makam, General Manager, Global Blood Solutions, Terumo BCT. "It's a new way to be more efficient for blood centers, for processing whole blood into its components including platelets. Reveos will help blood centers do more with the blood donors already walking through the doors."

SHERIDAN, WYOMING – November 09, 2024-Terumo Corporation, a leading medical technology company, has raised its financial forecast for the fiscal year ending March 31, 2025. This comes on the heels of impressive first-half results and favorable shifts in foreign exchange rates. The company now anticipates consolidated revenue of 1.01 trillion yen, a 30 billion yen increase from its previous estimate. This upward revision reflects better-than-expected revenue in the first and second quarters, coupled with the yen's depreciation exceeding initial projections.

SHERIDAN, WYOMING – November 09, 2024 – Novartis, a global healthcare company, recently released promising data on its Kesimpta® (ofatumumab) treatment for relapsing multiple sclerosis (RMS). The findings, presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 Annual Meeting, highlight the long-term benefits of Kesimpta for both first-line and switch patients. Relapsing multiple sclerosis is a chronic disease that affects the central nervous system, disrupting the flow of information within the brain, and between the brain and body. It is characterized by periods of relapse (disease activity) and remission (recovery). Kesimpta is a targeted B-cell therapy that works by reducing the number of B-cells, a type of immune cell thought to play a key role in MS attacks.

Novartis' Iptacopan Shows Promising Results in Phase III Trial for IgA Nephropathy SHERIDAN, WYOMING – November 09, 2024 – Novartis, a global healthcare leader, has announced exciting news from its Phase III APPLAUSE-IgAN study. Iptacopan, an investigational oral medication, has demonstrated significant potential in treating IgA nephropathy (IgAN), a rare and progressive kidney disease. This breakthrough offers renewed hope for young adults living with this challenging condition. Understanding IgA Nephropathy IgAN, often diagnosed in young adults, is a complex autoimmune disease where the body's immune system mistakenly attacks the kidneys. This leads to inflammation and damage, potentially resulting in kidney failure. Current treatments have limitations in addressing the root cause of the disease, highlighting the urgent need for more effective therapies.

SHERIDAN, WYOMING – November 08, 2024 – Sanofi, a leading global biopharmaceutical company, has announced outstanding results for the third quarter of 2024, showcasing robust financial performance and significant progress in its innovative product pipeline. The company's dedication to providing healthcare solutions for patients worldwide is reflected in its impressive double-digit sales growth and groundbreaking achievements in research and development. Sanofi's Q3 2024 sales surged by 15.7% at constant exchange rates (CER), reaching €13,438 million. Business earnings per share (EPS) also saw a significant increase, rising by 12.2% on a reported basis and 17.6% at CER to reach €2.86. This strong performance was fueled by better-than-expected vaccine sales, particularly for influenza and Beyfortus (RSV), and the continued strong growth of Dupixent, the company's leading immunology drug.

SHERIDAN, WYOMING – November 8, 2024 – Sanofi, a global biopharmaceutical company, is taking a bold stance in the fight against cancer by launching a comprehensive program designed to support employees impacted by the disease. Recognizing the profound impact cancer can have on individuals and their families, Sanofi's "Cancer & Work: Acting Together" initiative provides a 360° approach to addressing the financial, emotional, social, and professional needs of its colleagues. "We're creating an environment where everyone is supported to bring their best self to work," says a Sanofi spokesperson. This commitment is evidenced by Sanofi's participation in Publicis' #WorkingWithCancer global pledge, a public declaration to combat cancer and its associated stigmas in the workplace.

SHERIDAN, WYOMING – November 7, 2024 – In an era marked by growing health concerns and disparities, Tanzania is taking proactive strides to bolster its healthcare system. Through strategic investment in medical education and capacity building, the nation is fostering a skilled healthcare workforce to address its unique challenges and improve the well-being of its citizens. A collaborative endeavor between the Tanzanian Ministry of Health, Siemens Healthineers, and Muhimbili National Hospital (MNH) has yielded a specialized training program for medical engineers and radiographers. Over the past two years, this initiative has empowered more than 100 healthcare professionals with advanced skills in operating state-of-the-art imaging equipment.